LYKALABS

The stock has been placed in Enhanced Surveillance Measure (ESM) list ESM - II (35).

Lyka Labs Ltd.

NSE: LYKALABS

BSE: 500259

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

73.59-1.5 (-2.00%)

25 Aug, 2:29 PM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

6.4 / 100

Value Score

28.3 / 100

Price Momentum Score

39.2 / 100

QVM Score

8.3 / 100

Key Metrics

Market Cap

271.47

P/E (TTM)

P/B

2.94

P/S (TTM)

1.97

EV/EBITDA

CAPE (5Y)

278.98

ROE (TTM)

-10.24

ROCE (TTM)

-8.44

ROA (TTM)

-5.72

Avg 3Y ROE

2.81

Earnings 3Y CAGR

22.48

Sales 3Y CAGR

15.90

Sales 5Y CAGR

3.15

Debt/Equity

0.53

Consensus TP

Strong Buy %

Promoter Holding

58.45

Pledged %

0.00

Stock Analysis

Fundamental analysis overview of Lyka Labs Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Low Debt to Equity, not much change from last year

The company has low Debt to Equity of 0.53 as on 30 Jun 2026 and Debt to Equity increased marginally by 0.15 in the last 1 year

What is Debt to Equity?

Negative

Stock is fairly expensive with negative EPS on a trailing 12-month basis

Earnings yield of -3.28% indicates that the stock is very expensive and has a negative EPS on a trailing 12-month basis

What is Earnings yield (E/P)?

Low and declining ROE

The company reported low ROE of -10.24% for 12-month ended 30 Jun 2026 and ROE declined by -1956 bps from 1 year ago

What is ROE (FY)?

Low and declining operating margin

The company reported low operating margin of -7.97% for 12-month ended 30 Jun 2026 and operating margin declined by -1560 bps from 1 year ago

What is Operating profit margin?

Low revenue growth and lower than median growth of industry

The company delivered moderate revenue growth of -2.6% for 12-month ended 30 Jun 2026 and the growth was 13.19 percentage points lower than median growth of industry

What is Sales growth (1Y)?

Median: 10.59

Value -2.6

-99.6111701.8

Low EPS growth and lower than median growth of industry

The company delivered moderate EPS growth of -219.68% for 12-month ended 30 Jun 2026 and the growth was 226.88 percentage points lower than median growth of industry

What is EPS growth (1Y)?

Low dividend yield

The company has a low dividend yield of 0.0%

What is Dividend yield?

Neutral

Company's earnings are of moderate quality

Earnings quality score of 53.9 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

53.9 / 100

Financial Snapshot

See detailed analysis

Multi-year trends for Lyka Labs Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Lyka Labs Ltd. Shareholding Pattern

Quarterly breakdown of Lyka Labs Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Promoter	19.88	19.88	19.88	19.88	19.88	19.88	20.00	20.04	47.79	47.80	47.59	47.59	51.00	54.58	54.81	54.81	54.81	58.10	58.10	58.10	58.16	58.16	58.16	58.16	58.16	58.45
Indian Promoter	19.88	19.88	19.88	19.88	19.88	19.88	20.00	20.04	47.79	47.80	47.59	47.59	51.00	54.58	54.81	54.81	54.81	58.10	58.10	58.10	58.16	58.16	58.16	58.16	58.16	58.45
Foreign Promoter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Institutions	4.16	4.15	3.97	3.97	3.97	3.97	3.92	1.60	2.31	4.75	4.57	4.37	3.92	0.58	0.59	0.79	0.98	0.90	0.82	0.82	0.90	0.83	0.84	0.84	0.96	0.83
Mutual Funds / UTI	0.01	0.01	-	0.01	0.01	0.01	1.39	0.01	0.73	3.54	3.54	3.54	3.31	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
FI/Bank/Insurance	0.47	0.46	0.47	0.46	0.46	0.46	0.46	0.46	0.46	0.46	0.46	0.46	0.43	0.40	0.40	0.40	0.40	0.37	0.28	0.28	0.28	0.28	0.28	0.28	0.28	0.28
Govt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FII	3.50	3.50	3.50	3.50	3.50	3.50	2.07	1.13	1.12	0.76	0.57	0.37	0.18	0.17	0.18	0.17	0.17	0.15	0.15	0.15	0.24	0.16	0.17	0.17	0.29	0.17
Other Institutions	0.18	0.18	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.21	0.40	0.37	0.37	0.37	0.37	0.37	0.37	0.37	0.37	0.37
Non-Institution	75.96	75.97	76.15	76.15	76.15	76.15	76.08	78.36	49.89	47.45	47.84	48.05	45.08	44.85	44.60	44.40	44.21	40.99	41.08	41.07	40.94	41.01	41.00	41.00	40.88	40.72
Bodies Corporate	4.94	4.85	1.97	5.06	4.95	1.63	6.47	34.91	7.33	4.68	3.87	3.77	4.63	5.40	5.49	5.95	5.78	5.48	5.08	4.90	5.44	5.25	4.17	4.35	4.47	4.39
Others (incl. Retail) No. of shareholders	71.02 19,454	71.12 19,848	74.18 19,666	71.09 19,515	71.20 19,204	74.52 21,975	69.61 20,508	43.45 27,537	42.56 26,006	42.77 26,751	43.97 28,208	44.28 28,301	40.45 26,607	39.45 26,977	39.11 26,441	38.45 26,214	38.43 25,522	35.51 25,529	36.00 28,735	36.17 28,898	35.50 28,271	35.76 27,988	36.83 27,564	36.65 26,981	36.41 26,559	36.33 29,172

Holdings and Presence

Indices and prominent investors with a stake in this stock.

Index Presence

Lyka Labs Ltd. is not part of any tracked index.

Prominent Investor Holdings

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Lyka Labs Ltd. shares as reported to NSE and BSE.

Name	Month	Transaction	Holding % pre transaction	Average price	Qty.	Transaction value
Nehal Narendra Gandhi Promoter	March-2023	Inter-se Transfer (Acquisition) 22nd Mar 2023	3.58 %	₹ 0.00	3.85 lac	₹ 0.00
Kunal N Gandhi Promoter & Director	October-2022	Inter-se Transfer (Acquisition) 11th Oct 2022	3.55 %	₹ 0.00	50.78 k	₹ 0.00
Narendra I Gandhi HUF Promoter	October-2022	Inter-se Transfer (Disposal) 11th Oct 2022	4.88 %	₹ 0.00	50.78 k	₹ 0.00

Corporate Actions

History of Lyka Labs Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

Dividend₹ 2.50/share
Record date: 10th Sep 1996Ex-date: 14th Aug 1996
Announced on: 12th Aug 1996
Dividend₹ 2.50/share
Record date: 11th Sep 1995Ex-date: 16th Aug 1995
Announced on: 22nd Aug 1995
Dividend₹ 2.50/share
Record date: 4th Sep 1994Ex-date: 7th Oct 1994
Announced on: 18th Aug 1994
Rights Issue(1 new shares @ ₹30 for 2 existing shares)
Ex-date: 22nd Oct 1993
Dividend₹ 2/share
Record date: 25th Aug 1993Ex-date: 27th Aug 1993

Company Profile

Overview of Lyka Labs Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Lyka Labs Limited is an India-based pharmaceutical company engaged in the development, manufacture and marketing of quality finished dosages. The Company manufactures pharmaceutical products such as Dry Powder, Liquid, Lyophilized Injections and External Preparations for several International Market...

Key personnel

Mr. Babulal JainD

Independent Chairman of the Board

Mr. Kunal Narendra GandhiD

Chief Executive Officer, Managing Director, Executive Director

Mr. Yogesh B. ShahD

Chief Financial Officer, Whole-Time Director

Mr. Prashant GodhaD

Additional Director

Mr. Shashil MendonsaD

Additional Director

Shri. Vinod S. ShanbhagD

Additional Independent Director

Mr. Neeraj GolasD

Additional Non-Executive Independent Director

Ms. Archana YadavD

Additional Non-Executive Independent Women Director

View all

Incorporated on

29 Dec 1976

Last Annual

31 Mar 2026

Last Interim

30 Jun 2026

No. of Employees

648

IPO date

09 Feb 1995

Free Float

1,43,18,876

Website

https://www.lykalabs.com/

Phone no.

+912266112200

Address

Ground floor, Spencer Building,, 30, Forjett Street, Grant Road (West), MUMBAI, 400036, India

Frequently Asked Questions

What is the current share price of Lyka Labs Ltd.?

The current share price of Lyka Labs Ltd. is ₹ 73.59 as of 25 Aug 2026.

What is the market capitalisation of Lyka Labs Ltd.?

The market capitalisation of Lyka Labs Ltd. stands at ₹ 271.47 Cr.

What is the PE ratio of Lyka Labs Ltd.?

The Price-to-Earnings (PE) ratio of Lyka Labs Ltd. is - as of the latest trailing twelve months data.

What is the ROE and ROCE of Lyka Labs Ltd.?

Lyka Labs Ltd. has a Return on Equity (ROE) of -10.24% and a Return on Capital Employed (ROCE) of -8.44% as per the latest financial reports.

What is the 52-week high and low of Lyka Labs Ltd.?

The 52-week high of Lyka Labs Ltd. is - and the 52-week low is -.

What is the dividend yield of Lyka Labs Ltd.?

The dividend yield of Lyka Labs Ltd. is 0.00% based on the current market price.

What is the FII and DII holding in Lyka Labs Ltd.?

Foreign Institutional Investors (FII) hold 0.17%, Domestic Institutional Investors (DII) hold 0.29% and retail/public investors hold 36.33% of Lyka Labs Ltd. shares.

What sector does Lyka Labs Ltd. belong to?

Lyka Labs Ltd. operates in the Healthcare sector.

What is the beta of Lyka Labs Ltd.?

The beta of Lyka Labs Ltd. is 1.09, indicating its price volatility relative to the broader market. Over the past 1 year, Lyka Labs Ltd. has delivered an absolute return of -24.54%.

What is the RSI of Lyka Labs Ltd.?

The 14-day Relative Strength Index (RSI) of Lyka Labs Ltd. is 67.41, placing it approaching overbought territory. An RSI above 70 is considered overbought and below 30 is considered oversold.

Lyka Labs Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Lyka Labs Ltd. Shareholding Pattern

Holdings and Presence

Bulk, Block and Insider Trades

Corporate Actions

Company Profile

Frequently Asked Questions

Stock Analysis

Company Profile

Corporate Actions

Holdings and Presence